Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
COGT
COGT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
COGT News
Fairmount Funds Management Sells 3.5 Million Shares of Cogent
Feb 01 2026
NASDAQ.COM
Fairmount Funds Sells 3.5 Million Shares of Cogent Biosciences
Feb 01 2026
Fool
Pfizer Shares Rise on Upgraded Price Forecast
Jan 27 2026
Benzinga
Cogent Biosciences Receives FDA Breakthrough Therapy Designation
Jan 26 2026
Benzinga
Cogent Biosciences Insider Sells 65,000 Shares for $2.52 Million
Jan 11 2026
NASDAQ.COM
Cogent Biosciences' CLO Sells 65,000 Shares for $2.52 Million
Jan 11 2026
Fool
Cogent Biosciences Shares Surge in 2025 Amid Executive Stock Sales
Jan 02 2026
Barron's
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
Dec 31 2025
NASDAQ.COM
Cogent Submits NDA for Bezuclastinib in NonAdvanced Systemic Mastocytosis
Dec 30 2025
Globenewswire
Cogent Biosciences Submits NDA for Bezuclastinib in NonAdvanced Systemic Mastocytosis
Dec 30 2025
Newsfilter
Analyzing the Best-Performing Russell 2000 Stocks in Relation to the Zacks Rank
Dec 12 2025
NASDAQ.COM
Cogent Biosciences (COGT) Price Target Raised by 10.58% to $48.13
Dec 07 2025
NASDAQ.COM
Cogent Biosciences' Bezuclastinib Shows Significant Symptomatic Improvement in NonAdvSM Patients
Dec 06 2025
Globenewswire
Cogent Biosciences' Bezuclastinib Shows Significant Symptomatic Improvement in NonAdvSM Patients
Dec 06 2025
Newsfilter
Biotech Stocks MODD, LAB, HOWL, COGT, LGVN, and ABCL Surge in After-Hours Trading - Nov 26
Nov 28 2025
NASDAQ.COM
Cogent Biosciences (COGT) Soars 144.5% Following Phase 3 Success of Bezuclastinib and $500M Capital Raise: Has the Bullish Outlook Shifted?
Nov 13 2025
Yahoo Finance
Show More News
